title: Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector.
abstract: The immunogenicity of recombinant canarypox (ALVAC) viral vectors within murine whole-cell tumor vaccines was evaluated using the T cell thymic lymphoma STF10 and the B16 melanoma. Tumor cells were modified with the recombinant ALVAC vectors and injected into syngeneic mice. Control mice receiving cells alone all developed tumors, while mice injected with tumor variants bearing parental and recombinant vectors either completely rejected their tumors, or exhibited a significant delay in tumor formation. Rechallenge of mice receiving STF10-variant vaccines yielded a protective effect against parental tumor cells only when a modified regimen incorporating two vaccinations was utilized. Notably, the parental ALVAC virus was equivalent to all other recombinant ALVAC viruses in conferring antitumor immunity when using a prime-and-boost protocol. Tumorigenicity experiments in nude mice revealed that the effector mechanism mediating rejection of tumor cells bearing ALVAC vectors is multifactorial, in that the immunogenicity of STF10/ALVAC vaccines is reduced, but not completely abolished in these mice. Finally, in vitro experiments revealed that cytotoxic T cells specific for parental STF10 cells could be generated as a result of in vivo immunization with STF10/ALVAC vaccines.
authors.affiliation: Institute of Medical Science, University of Toronto, Ontario, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Ghose
authors.forename: E
authors.initials: E
authors.lastname: Iakhnina
authors.forename: D
authors.initials: D
authors.lastname: Spaner
authors.forename: J
authors.initials: J
authors.lastname: Tartaglia
authors.forename: N L
authors.initials: NL
authors.lastname: Berinstein
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D018150:Avipoxvirus / Q000235:genetics / Q000276:immunology*; D018122:B7-1 Antigen / Q000096:biosynthesis / Q000235:genetics; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D005822:Genetic Vectors / Q000276:immunology*; D007117:Immunization, Secondary; D018664:Interleukin-12 / Q000096:biosynthesis / Q000235:genetics; D016399:Lymphoma, T-Cell / Q000235:genetics / Q000276:immunology; D008546:Melanoma, Experimental / Q000235:genetics / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014161:Transduction, Genetic; D014407:Tumor Cells, Cultured
chemical_list: D000914:Antibodies, Viral; D018122:B7-1 Antigen; D019496:Cancer Vaccines; D018664:Interleukin-12